These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21399893)

  • 1. Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas.
    Tufail R; Jorda M; Zhao W; Reis I; Nawaz Z
    Breast Cancer Res Treat; 2012 Feb; 131(3):743-50. PubMed ID: 21399893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
    Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
    Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
    Buxant F; Engohan-Aloghe C; Noël JC
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of DNA methylation marker of paired-like homeodomain transcription factor 2 and growth receptors in invasive ductal carcinoma of the breast.
    Wan Abdul Rahman WF; Fauzi MH; Jaafar H
    Asian Pac J Cancer Prev; 2014; 15(19):8441-5. PubMed ID: 25339043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and clinical significance of LRP16 gene in human breast cancer].
    Liao DX; Han WD; Zhao YL; Pu YD; Mu YM; Luo CH; Li XH
    Ai Zheng; 2006 Jul; 25(7):866-70. PubMed ID: 16831279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic potential of keratin 18 in breast cancer associated with tumor dedifferentiation, and the loss of estrogen and progesterone receptors.
    Ha SA; Lee YS; Kim HK; Yoo J; Kim S; Gong GH; Lee YK; Kim JW
    Cancer Biomark; 2011; 10(5):219-31. PubMed ID: 22699783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
    Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
    Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
    Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
    Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
    Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
    Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.
    Hefti MM; Hu R; Knoblauch NW; Collins LC; Haibe-Kains B; Tamimi RM; Beck AH
    Breast Cancer Res; 2013; 15(4):R68. PubMed ID: 23971947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptors in breast cancer: more than estrogen receptors.
    Lamb CA; Vanzulli SI; Lanari C
    Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies.
    Milosevic J; Klinge J; Borg AL; Foukakis T; Bergh J; Tobin NP
    BMC Cancer; 2013 Oct; 13():473. PubMed ID: 24119434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
    Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
    Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
    Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
    Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.